SEVERNA PARK, MD --(Marketwired - October 14, 2013) - Michael Thomas, chief executive officer of iSonea Ltd. (ASX: ISN) (OTCQX: ISOAY) and mHealth expert, will speak at MobileCON(TM) 2013 powered by CTIA on the "Power of M2M" (machine to machine) and "Wearables: Beyond the Handset."
MobileCON 2013 is scheduled for Oct. 16-18 at the San Jose Convention Center (Calif.) and will entertain more than 8,000 guests.
Thomas has more than 24 years of health care industry experience specializing in medical devices, health information technology, health care services and medical technology consulting.
Most recently, the self-proclaimed serial entrepreneur has created the AsthmaSense® smartphone application to aid in asthma monitoring and the soon-to-be released AirSonea™, a revolutionary smartphone-enabled device for monitoring wheeze. Wheeze is a cardinal sign of asthma and is associated with airway obstruction.
On Oct. 16 beginning at noon PT, Thomas will join The Telecom Council of Silicon Valley to address "Wearables: Beyond the Handset." The seasoned executive will showcase iSonea's products to potential investors, Silicon Valley executives and media.
The following day, Oct. 17 at 3:30 p.m. PT, Thomas will conduct a thought-leadership session entitled "M2M Powers Self Monitoring to Improve Health Outcomes." The session will address the power of mHealth technology and remote sensors that enable patients with chronic diseases to self-monitor and improve long term health outcomes.
To register for MobileCON, please visit https://ctia.itnint.com/MC13/regonline/RegLogin.aspx.
For more information about Michael Thomas and iSonea, visit the newsroom.
About iSonea Limited:
iSonea Limited (ASX: ISN) (OTCQX: ISOAY) is an emerging medical technology company developing innovative, non-invasive devices and mobile health apps to improve the management of chronic, costly respiratory disorders such as asthma and COPD. By leveraging iSonea's proprietary Acoustic Respiratory Monitoring™ (ARM) technology with its AsthmaSense™ mobile applications, iSonea is creating a better monitoring system -- enabling anyone, anywhere, at any time to monitor breathing distress symptoms, in order to take action. iSonea's ARM devices have been cleared for use by the U.S. Food and Drug Administration, the Australian TGA and the European Union. For more information, please visit www.AsthmaSense.com or www.iSoneaMed.com.
Forward Looking Statements
The following files are available for download: